Sveriges mest populära poddar
Blood Podcast
Blood Podcast

Malignancy risk from genetically modified immune effector cells, p53 immunohistochemistry as a new tool in AML, and phenotypic escape from CD19-directed immunotherapies.

22 min•7 juli 2022

Om avsnittet

Today we’ll learn more about the risk of subsequent malignancies in patients treated with genetically modified immune effector cells, discuss how p53 immunohistochemistry can be a global readout for TP53 alterations in AML, and uncover the role of CD19-negative CD22-positive B-cell progenitors in immune escape from CD19-directed therapies.

Fler avsnitt

Visa alla avsnitt av Blood Podcast

Designing Durable Remissions in Relapsed AML and Follicular Lymphoma

16 min

Dose Makes the Cure: Venetoclax in Ph- ALL

14 min

Exploiting Vulnerabilities in High‑Risk MM and Mapping the Red Cell Interactome

30 min

MYB driven ALL and Venetoclax-Azacitidine damage to Bone Marrow

25 min

Predictive Markers of Glofitamab Resistance in R/R B-NHL

16 min

Better Together: Adding daratumumab for AL Amyloidosis and and Mezigdomide for MM

26 min

Balancing Infection and Thrombosis: Bispecific Antibodies and the Many Roles of HRG

15 min

Cost-Effectiveness of Current SCD Treatments and Potential Therapeutic Targets for Fetal Hemoglobinopathies

33 min

HLH-like toxicities after CAR-T and Structure-Function Relationships of FNAIT

17 min

FLT3-ITD microclones in AML and Results from the RESET-PV trial

14 min

Blood Podcast med American Society of Hematology finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.